Reviewing Array BioPharma Inc. (ARRY)’s and Affimed N.V. (NASDAQ:AFMD)’s results

Both Array BioPharma Inc. (NASDAQ:ARRY) and Affimed N.V. (NASDAQ:AFMD) are each other’s competitor in the Biotechnology industry. Thus the contrast of their analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Array BioPharma Inc. 180.09M 25.71 111.47M -0.65 0.00
Affimed N.V. N/A 0.00 N/A -0.70 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Array BioPharma Inc. and Affimed N.V.


Table 2 hightlights the return on assets, return on equity and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Array BioPharma Inc. -61.90% -56.7% -28.2%
Affimed N.V. 0.00% -82.1% -63.5%

Risk & Volatility

Array BioPharma Inc. has a 1.12 beta, while its volatility is 12.00% which is more volatile than S&P 500. Competitively, Affimed N.V.’s beta is 3.65 which is 265.00% more volatile than S&P 500.


The current Quick Ratio of Array BioPharma Inc. is 5.6 while its Current Ratio is 5.6. Meanwhile, Affimed N.V. has a Current Ratio of 3.7 while its Quick Ratio is 3.6. Array BioPharma Inc. is better positioned to pay off its short-term and long-term debts than Affimed N.V.

Analyst Recommendations

The next table highlights the delivered recommendations and ratings for Array BioPharma Inc. and Affimed N.V.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Array BioPharma Inc. 0 1 2 2.67
Affimed N.V. 0 0 2 3.00

Array BioPharma Inc.’s upside potential currently stands at 17.81% and an $25 average price target. Competitively the average price target of Affimed N.V. is $4.5, which is potential 31.58% upside. Based on the analysts belief we can conclude, Affimed N.V. is looking more favorable than Array BioPharma Inc.

Institutional and Insider Ownership

The shares of both Array BioPharma Inc. and Affimed N.V. are owned by institutional investors at 98.1% and 42.9% respectively. Insiders owned 0.4% of Array BioPharma Inc. shares. Comparatively, insiders own roughly 16.7% of Affimed N.V.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Array BioPharma Inc. -3.14% -9.82% 7.15% -13.46% 42.87% 20.55%
Affimed N.V. -20.09% -9.6% -25.42% 70.48% 88.42% 175.38%

For the past year Array BioPharma Inc. was less bullish than Affimed N.V.


On 6 of the 11 factors Array BioPharma Inc. beats Affimed N.V.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companyÂ’s drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus. Its drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer. In addition, the company is developing ARRY-797, a p38 inhibitor, which is in Phase II clinical trials for Lamin A/C-related dilated cardiomyopathy; Motolimod/VTX-2337, a Toll-like receptor that is under Phase II clinical studies for cancer; and Prexasertib/LY2606368, a CHK-1 inhibitor, which is in Phase II clinical studies for cancer, as well as ARRY-382, a CSF1R inhibitor that is under Phase I/II clinical trial to treat cancer. Further, it is developing GDC-0575, a CHK-1 inhibitor that is in Phase Ib clinical trial for the treatment of cancer; LOXO-292, a RET inhibitor, which is under Phase I clinical trials to treat cancer; and LOXO-195, a NTRK inhibitor that is under Phase I clinical trials to treat cancer. Array BioPharma Inc. has a collaboration agreement with Amgen, Asahi Kasei Pharma Corporation, Loxo Oncology, and Mirati Therapeutics, Inc. The company was founded in 1998 and is headquartered in Boulder, Colorado.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. Its lead candidate is AFM13, a natural killer cell (NK-cell) TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma. Its product candidates also comprise AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma and acute lymphocytic leukemia; and AMV564, a CD33/CD3-specific T-cell TandAb for the treatment of acute myeloid leukemia and other hematologic malignancies. The company has license agreements with Amphivena Therapeutics, Inc., Deutsches Krebsforschungszentrum, and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and collaboration with Merck Sharp & Dohme B.V. It also has a clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate AFM13 in combination with MD AndersonÂ’s NK-cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.